Tocilizumab Induces Rapid, Sustained Improvement of Inflammatory Markers in COVID-19, With Clinical Improvement in Most Patients.

Morin, Scott J; Jani, Chinmay; Rupal, Arashdeep; Singh, Harpreet; Bourque, Daniel; Colgrove, Robert C

Morin, Scott J; Jani, Chinmay; Rupal, Arashdeep; Singh, Harpreet; Bourque, Daniel; Colgrove, Robert C.

Morin SJ; Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA.
Jani C; Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA.
Rupal A; Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA.
Singh H; Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA.
Bourque D; Department of Infectious Diseases, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA.
Colgrove RC; Department of Infectious Diseases, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA.

Am J Ther ; 28(5): e592-e596, 2021 07 05.

Article in English | MEDLINE | ID: covidwho-1522389

Subject(s)

COVID-19 Drug Treatment; Antibodies, Monoclonal, Humanized; Humans; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Type of study: Prognostic study Limits: Humans Language: English Journal: Am J Ther Journal subject: Therapeutics Year: 2021 Document Type: Article Affiliation country: MJT.0000000000001412

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google